Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pegcetacoplan (APL-2) for paroxysmal nocturnal haemoglobinuria Pegcetacoplan (APL-2) Paroxysmal nocturnal haemoglobinuria (PNH) Haematology 2019 View  |  Download
Pegcetacoplan for treating amyotrophic lateral sclerosis Pegcetacoplan (APL-2) Amyotrophic lateral sclerosis Neurology 2023 View  |  Download
Pegcetacoplan for treating geographic atrophy Pegcetacoplan (APL-2) Geographic atrophy Ophthalmology 2021 View  |  Download
PEGPH20 in addition to Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Ductal Adenocarcinoma Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Pegvorhyaluronidase alfa (PEGPH20) Pancreatic cancer Gastrointestinal Cancer 2018 View  |  Download
Pegunigalsidase alfa for Fabry disease – first-line PRX-102 (Pegunigalsidase alfa) Fabry disease Endocrine Nutritional and Metabolic Disorders , Genetic Disorders 2020 View  |  Download
Pegzilarginase for Arginase-1 deficiency Pegzilarginase (AEB1102; Loargys) Hyperargininemia Endocrine Nutritional and Metabolic Disorders 2021 View  |  Download
Pembrolizumab (Keytruda) for advanced gastric or gastroesophageal junction adenocarcinoma – first line Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Pembrolizumab (KEYTRUDA) for advanced, metastatic oesophageal cancer – second line Pembrolizumab (Keytruda; MK-3475) Gastro-oesophageal junction cancer , Oesophageal cancer Gastrointestinal Cancer , Head and Neck Cancer 2017 View  |  Download
Pembrolizumab (Keytruda) for metastatic castration‐resistant prostate Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2017 View  |  Download
Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
1 2 72 73 74 75 76 113 114
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications